Novartis: 3 Key Takeaways for Long-Term Investors
On its third-quarter 2026 earnings call, held on Oct. 27, 2026, Novartis (NYSE:NVS) raised its full-year 2026 core operating income guidance after delivering 4% net sales growth. This performance matters for long-term investors because the pharmaceutical giant is demonstrating that expanding sales from recently launched drugs can successfully replace revenue from older medicines losing patent protection. Three key insights from management explain how the company is maintaining its growth trajectory. Novartis raised its full-year 2026 core operating income guidance, which tracks non-GAAP (adjusted) operating profit before one-time items, to in-line to low-single-digit growth, up from a previously projected decline. This operational shift shows that rising sales of priority medicines are offsetting patent expirations for key legacy treatments. Management upgraded peak sales projections for key pipeline drugs, including Rhapsido for skin conditions such as chronic spontaneous urticaria (CSU), where hives appear without clear triggers. Promising trial results for remibrutinib in relapsing multiple sclerosis (RMS), a central nervous system disorder, further reinforce the company's ability to replace aging therapies. Continue reading